Sentences with phrase «graft rejection»
"Graft rejection" is when the body's immune system recognizes and attacks a transplanted organ or tissue as if it's a foreign substance or invader, causing it to fail. Full definition
Depletion of CD4 + T cells by in vivo administration of anti-CD4 monoclonal antibodies (12, 13) or deletion of the CD4 gene (14, 15) have demonstrated the importance of CD4 + T cells in corneal graft rejection.
journals.lww.com
Both CsA and tacrolimus are T cell activation inhibitors initially developed for their systemic use in preventing graft rejection after organ transplantation.
«How common chemo drug thwarts graft rejection in bone marrow transplants.»
Given to the patient shortly before the transplant, the infusion of antibodies theoretically reduces the host's residual T cells, minimizing the risk of graft rejection while eliminating T cells from the donor to thwart GVHD.
Apoptosis has been implicated as a T cell - dependent immune effector mechanism in various forms of organ graft rejection (29 — 31).
In pre-clinical studies conducted by the researchers, a one - time, local injection of the hydrogel - drug combo prevented graft rejection for more than 100 days compared to 35.5 days for recipients receiving only tacrolimus and 11 days for recipients without treatment or only receiving hydrogel.
The precise immune mechanisms that mediate corneal graft rejection remain poorly understood even after 50 years of research in laboratory animals.
While no longer a diabetes patient, her transplant necessitates the taking of immunosuppressants, which are prescribed to prevent islet graft rejection and promote immune tolerance.
«At least half of transplanted kidneys are lost through chronic graft rejection, usually within 10 years.
Low - dose donor CD8 + cells in the CD4 - depleted graft prevent allogeneic marrow graft rejection and severe graft - versus - host disease for chronic myeloid leukemia patients in first chronic phase.
Cohen died in 1993, but Steinman went on to head the laboratory that pioneered the investigation of dendritic cells, leading to important treatments for human disease using dendritic cell - and immune - based vaccines and therapies for such conditions as graft rejection, resistance to tumours, autoimmune diseases and other infections, such as the first dendritic, cell - targeted vaccine against HIV.
They matched the major histocompatibility complex (MHC) between donor and recipient monkeys to see if that would mitigate graft rejection.
However, closer scrutiny of these studies raises questions about the role of CD4 + T cells as the sole mediators of corneal graft rejection, as corneal allografts undergo immune rejection in 33 % of the mice and 64 % of the rats treated with anti-CD4 monoclonal antibody (12, 13) and in 45 % of the CD4 KO mice (14).
In theory, the developing fetus with an immature immune system should be a prime target for successful transplantation, since the risk of graft rejection is low and the need for long - term immunosuppressive therapy may be avoided.
«Finding the optimal conditions to avoid interfering with immune cells working to eradicate cancer while preventing graft rejection and GVHD is the holy grail of bone marrow transplant,» says Leo Luznik, M.D., associate professor of oncology at the Johns Hopkins Kimmel Cancer Center.
Neither Baby Fae's parents nor the public were adequately informed of the double - barreled danger of host - graft rejection and organ destruction from medication.
It remains unclear whether the secret to Ildstad's recipe is the facilitating cells or the timing of a certain chemotherapy drug, called cyclophosphamide, that is used to prevent graft rejection and GvHD.
As previously reported, CD4 + T cells play a major role in corneal graft rejection, yet approximately half of corneal allografts undergo rejection in the absence of CD4 + T cells (3, 12 — 14).
The notion that CD4 + T cells might be the pivotal mediators of corneal graft rejection arose from studies demonstrating the close correlation between delayed - type hypersensitivity (DTH), a classical CD4 + T cell - mediated immune process, and corneal graft rejection in rodents (10, 11).
In the last decade, Foxp3 + Treg cells have raised the hope for novel cell - based therapies to achieve tolerance in clinical settings of unwanted immune responses such as autoimmunity and graft rejection.
As next steps, researchers will need to confirm that the findings are consistent in humans and also will investigate how exactly maternal T cells cause a graft rejection.
The same techniques could be used to treat organ - graft rejection.
In dogs, graft rejection is usually severe and this procedure is not routinely performed.